Cargando…

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

INTRODUCTION: To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Riju, Hahn, Beth, Stanford, Richard H., White, John, Essoi, Breanna, Hunter, Alyssa Goolsby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967324/ https://www.ncbi.nlm.nih.gov/pubmed/32026409 http://dx.doi.org/10.1007/s41030-019-00099-0

Ejemplares similares

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
por: Hahn, Beth, et al.
Publicado: (2019)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
por: Hahn, Beth, et al.
Publicado: (2019)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
por: Han, MeiLan K., et al.
Publicado: (2018)

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
por: Buikema, Ami R., et al.
Publicado: (2018)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
por: Shin, Hong-Joon, et al.
Publicado: (2023)

LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
por: Chen, Ching-Yi, et al.
Publicado: (2020)

Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity
por: Mapel, Douglas W, et al.
Publicado: (2015)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study
por: Taylor, Douglas C.A., et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
por: Moretz, Chad, et al.
Publicado: (2019)

Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis
por: Zhang, Chuchu, et al.
Publicado: (2021)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021)

Dalai Lama
Publicado: (2020)

Dalaï-Lama
Publicado: (2020)

Lamas in loops
por: Lai, Eric C.
Publicado: (2003)

Observational vignette study to examine patient and healthcare provider perceived impact of asthma-related exacerbations in the US
por: Johnson, Phaedra T., et al.
Publicado: (2019)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Spirometry for the diagnosis of airway obstruction in patients with risk factors for COPD: the GOLD and lower limit of normal criteria
por: Grafino, Monica, et al.
Publicado: (2021)

Dalai Lama at CERN
Publicado: (1983)

Visit of Dalay Lama
Publicado: (1983)

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
por: Palli, Swetha R, et al.
Publicado: (2021)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l46tnk1kn5ffdsbn3hmmibs8iv